The therapeutic potential of inhibiting TSLP in patients with asthma was also assessed by using Tezepelumab, which is a fully humanized monoclonal antibody (mAb) against TSLP that has been approved by the FDA for severe asthma treatment in the U.S. under the brand name of Tezspire in 2021. This evidence concerns the gene TSLP and asthma.